<?xml version="1.0" encoding="UTF-8" ?><!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
	"http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" >
<html><head><title>Side-by-side differences</title><link rel="stylesheet" type="text/css" href="/archive/history.css" /><link rel="stylesheet" type="text/css" href="/archive/sdiff.css" /><script type="text/javascript" src="/archive/common.js"></script><script type="text/javascript" src="/archive/sdiff.js"></script><style>table.sdiff div.sdl0 { margin-left: 0em; }
table.sdiff div.sdl1 { margin-left: 2em; }
table.sdiff div.sdl2 { margin-left: 4em; }
table.sdiff div.sdl3 { margin-left: 6em; }
table.sdiff div.sdl4 { margin-left: 8em; }
table.sdiff div.sdl5 { margin-left: 10em; }
table.sdiff div.sdl6 { margin-left: 12em; }
table.sdiff div.sdl7 { margin-left: 14em; }
table.sdiff div.sdl8 { margin-left: 16em; }
table.sdiff div.sdl9 { margin-left: 18em; }
table.sdiff div.sdl10 { margin-left: 20em; }
table.sdiff div.sdl11 { margin-left: 22em; }
table.sdiff div.sdl12 { margin-left: 24em; }
table.sdiff div.sdl13 { margin-left: 26em; }
table.sdiff div.sdl14 { margin-left: 28em; }
table.sdiff div.sdl15 { margin-left: 30em; }
table.sdiff div.sdl16 { margin-left: 32em; }
table.sdiff div.sdl17 { margin-left: 34em; }
table.sdiff div.sdl18 { margin-left: 36em; }
table.sdiff div.sdl19 { margin-left: 38em; }
</style></head><body class="sdiff">
<div class="navTop"><table class="navTopTriptych"><tr><td class="navTopTriptychL"><img src="/archive/ctgov_logo_ttl.gif" alt="ClinicalTrials.gov" width="360" height="47" /></td><td class="navTopTriptychC" style="background-image: url(/archive/ctgov_logo_ttm.gif)" /><td class="navTopTriptychR"><img src="/archive/ctgov_logo_ttr.gif" alt="Linking patients to medical research" width="314" height="47" /></td></tr></table></div>
<div id="sdiff-links" class="navLinks" /><div id="navLinks" class="navLinks"><a href="/archive/NCT00001300">&#8592; History of this study</a><a href="http://clinicaltrials.gov/show/NCT00001300">&#8593; Current version of this study</a></div><form><div id="sdiff-js-menu" style="display: none"><div><input type="checkbox" id="sdiff-HideUnch-cb" name="sdiff-HideUnch" value="true" onclick="SDiffUpdateHideUnch(&#39;sdiff-HideUnch-cb&#39;)" /><span class="sdiff-label" onclick="SDiffToggleHideUnch(&#39;sdiff-HideUnch-cb&#39;)"> Hide unchanged portions (except top/bottom lines)</span></div><div><input type="checkbox" id="sdiff-HideNonMain-cb" name="sdiff-HideNonMain" value="true" onclick="SDiffUpdateHideNonMain(&#39;sdiff-HideNonMain-cb&#39;)" /><span class="sdiff-label" onclick="SDiffToggleHideNonMain(&#39;sdiff-HideNonMain-cb&#39;)"> Hide non-essential portions (contact info, locations, etc.)</span></div><div style="display:none"><input type="checkbox" id="sdiff-HideKey-cb" name="sdiff-HideKey" value="true" onclick="SDiffUpdateHideKey(&#39;sdiff-HideKey-cb&#39;)" /><span class="sdiff-label" onclick="SDiffToggleHideKey(&#39;sdiff-HideKey-cb&#39;)"> Hide key</span></div></div><h1>Changes to NCT00001300 on 2007_01_22</h1><div id="sdiff-key"><div id="sdiff-key-mb"><img id="sdiff-key-minmax" onclick="SDiffToggleHideKey(&#39;sdiff-HideKey-cb&#39;)" src="/archive/minmax.gif" alt="[+/-]" width="16" height="16" style="display:none" /><h2>Key</h2></div><img id="sdiff-key-img" src="/archive/sdiff-key.gif" alt="Key" /></div><div class="sdiff-changedesc"><em>Type of info changed: </em>Recruitment, Misc.</div><div class="sdiff-view" id="sdiff-full" style="display: none"><table class="sdiff navLinks"><colgroup><col id="h-col" /><col id="a-col" /><col id="b-col" /></colgroup><tr><th class="sdiff-h" /><th class="sdiff-a"><div class="sdiff-prev"><a href="/archive/NCT00001300/2006_07_14/changes" title="Show changes from prior version to this one"><img src="/archive/prev.gif" alt="[Previous]" width="23" height="19" /></a></div><h2>Before</h2><h3><a href="/archive/NCT00001300/2006_07_14">(Updated 2006_07_14)</a></h3></th><th class="sdiff-b"><div class="sdiff-next"><a href="/archive/NCT00001300/2008_03_03/changes" title="Show changes from this version to next one"><img src="/archive/next.gif" alt="[Next]" width="23" height="19" /></a></div><h2>After</h2><h3><a href="/archive/NCT00001300/2007_01_22">(Updated 2007_01_22)</a></h3></th></tr>
<tr class="sdiff-unc" id="sdiff-chunk-f1"><td class="sdiff-h">1</td>
<td class="sdiff-a"><img id="sdiff-collapse-f0A-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-f0&#39;)" style="display:none" /><img id="sdiff-collapse-f0A-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f0&#39;)" style="display:none" /><div class="sdl0 sds">&lt;clinical_study&gt;</div>
<div id="sdiff-collapse-f0A-cdiv" class="sdiff-collapsed" title="The middle 214 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f0&#39;)" style="display:none"></div><div id="sdiff-collapse-f0A-ediv" class="sdiff-expanded"><div class="sdl1 sds">&lt;study_id&gt;</div>
<div class="sdl2 sds">&lt;org_name&gt;</div>
<div class="sdl3">  NIHCC</div>
<div class="sdl2 sdz">&lt;/org_name&gt;</div>
<div class="sdl2 sds">&lt;org_full_name&gt;</div>
<div class="sdl3">  National Institutes of Health Clinical Center (CC)</div>
<div class="sdl2 sdz">&lt;/org_full_name&gt;</div>
<div class="sdl2 sds">&lt;org_study_id&gt;</div>
<div class="sdl3">  920210</div>
<div class="sdl2 sdz">&lt;/org_study_id&gt;</div>
<div class="sdl2 sds">&lt;secondary_id&gt;</div>
<div class="sdl3">  92-C-0210</div>
<div class="sdl2 sdz">&lt;/secondary_id&gt;</div>
<div class="sdl2 sds">&lt;nct_id&gt;</div>
<div class="sdl3">  NCT00001300</div>
<div class="sdl2 sdz">&lt;/nct_id&gt;</div>
<div class="sdl1 sdz">&lt;/study_id&gt;</div>
<div class="sdl1 sds">&lt;brief_title&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl3">  A Randomized Study of the Effect of Adjuvant Chemotherapy With Doxorubicin and Ifosfamide With Mesna in the Treatment of High-Grade Adult Extremity Soft Tissue Sarcoma</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/brief_title&gt;</div>
<div class="sdl1 sds">&lt;official_title&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl3">  A Randomized Study of the Effect of Adjuvant Chemotherapy With Doxorubicin and Ifosfamide With Mesna in the Treatment of High-Grade Adult Extremity Soft Tissue Sarcoma</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/official_title&gt;</div>
<div class="sdl1 sds">&lt;study_sponsor&gt;</div>
<div class="sdl2 sds">&lt;lead_sponsor&gt;</div>
<div class="sdl3 sds">&lt;agency&gt;</div>
<div class="sdl4">  National Cancer Institute (NCI)</div>
<div class="sdl3 sdz">&lt;/agency&gt;</div>
<div class="sdl2 sdz">&lt;/lead_sponsor&gt;</div>
<div class="sdl1 sdz">&lt;/study_sponsor&gt;</div>
<div class="sdl1 sds">&lt;oversight_info&gt;</div>
<div class="sdl1 sdz">&lt;/oversight_info&gt;</div>
<div class="sdl1 sds">&lt;brief_summary&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl3">  Randomized study.  All patients must be randomized to treatment on Arms I and II within 3 months of definitive surgery on Regimen A.</div>
<div class="sdl3">  </div>
<div class="sdl3">  </div>
<div class="sdl3">        Regimen A:  Surgery followed, as indicated, by Radiotherapy.  Amputation; or limb-sparing resection followed by involved-field irradiation using megavoltage equipment with or without electron boost.</div>
<div class="sdl3">  </div>
<div class="sdl3">  </div>
<div class="sdl3">        Arm I:  2-Drug Combination Chemotherapy with Hematologic Toxicity Attenuation and Urothelial Protection.  Doxorubicin, DOX, NSC-123127; Ifosfamide, IFF, NSC-109724; with Granulocyte Colony Stimulating Factor (Amgen), G-CSF,</div>
<div class="sdl3">  </div>
<div class="sdl3">  </div>
<div class="sdl3">        NSC-614629; and Mesna, NSC-113891.</div>
<div class="sdl3">  </div>
<div class="sdl3">  </div>
<div class="sdl3">        Arm II:  Observation.  No adjuvant chemotherapy.</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/brief_summary&gt;</div>
<div class="sdl1 sds">&lt;detailed_descr&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl3">  Patients with primary, high-grade soft tissue sarcoma of the extremities will undergo treatment of their primary tumor with either amputation or limb-sparing surgery and radiotherapy, and then be randomized to either observation or adjuvant treatment with doxorubicin and ifosfamide with mesna (with G-CSF) for five cycles beginning post-operatively.  Local recurrence, disease-free survival and overall survival will be evaluated in this randomized two-arm trial.</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/detailed_descr&gt;</div>
<div class="sdl1 sds">&lt;status_block&gt;</div>
<div class="sdl2 sds">&lt;status&gt;</div>
<div class="sdl3">  Completed</div>
<div class="sdl2 sdz">&lt;/status&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl3">  2000-04</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/status_block&gt;</div>
<div class="sdl1 sds">&lt;start_date&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl3">  1992-06</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/start_date&gt;</div>
<div class="sdl1 sds">&lt;end_date&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl3">  2001-03</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/end_date&gt;</div>
<div class="sdl1 sds">&lt;last_follow_up_date&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/last_follow_up_date&gt;</div>
<div class="sdl1 sds">&lt;last_data_entry_date&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/last_data_entry_date&gt;</div>
<div class="sdl1 sds">&lt;phase_block&gt;</div>
<div class="sdl2 sds">&lt;phase&gt;</div>
<div class="sdl3">  Phase 3</div>
<div class="sdl2 sdz">&lt;/phase&gt;</div>
<div class="sdl1 sdz">&lt;/phase_block&gt;</div>
<div class="sdl1 sds">&lt;study_type&gt;</div>
<div class="sdl2">  Interventional</div>
<div class="sdl1 sdz">&lt;/study_type&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Treatment</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Efficacy Study</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  Sarcoma</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;intervention&gt;</div>
<div class="sdl2 sds">&lt;intervent_type&gt;</div>
<div class="sdl3">  Drug</div>
<div class="sdl2 sdz">&lt;/intervent_type&gt;</div>
<div class="sdl2 sds">&lt;primary_name&gt;</div>
<div class="sdl3">  doxorubicin</div>
<div class="sdl2 sdz">&lt;/primary_name&gt;</div>
<div class="sdl1 sdz">&lt;/intervention&gt;</div>
<div class="sdl1 sds">&lt;intervention&gt;</div>
<div class="sdl2 sds">&lt;intervent_type&gt;</div>
<div class="sdl3">  Drug</div>
<div class="sdl2 sdz">&lt;/intervent_type&gt;</div>
<div class="sdl2 sds">&lt;primary_name&gt;</div>
<div class="sdl3">  ifosfamide</div>
<div class="sdl2 sdz">&lt;/primary_name&gt;</div>
<div class="sdl1 sdz">&lt;/intervention&gt;</div>
<div class="sdl1 sds">&lt;intervention&gt;</div>
<div class="sdl2 sds">&lt;intervent_type&gt;</div>
<div class="sdl3">  Drug</div>
<div class="sdl2 sdz">&lt;/intervent_type&gt;</div>
<div class="sdl2 sds">&lt;primary_name&gt;</div>
<div class="sdl3">  mesna</div>
<div class="sdl2 sdz">&lt;/primary_name&gt;</div>
<div class="sdl1 sdz">&lt;/intervention&gt;</div>
<div class="sdl1 sds">&lt;eligibility&gt;</div>
<div class="sdl2 sds">&lt;criteria&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  DISEASE CHARACTERISTICS:</div>
<div class="sdl4">  </div>
<div class="sdl4">  Histologically proven AR and ESFT which includes: Classical, atypical and extraosseous Ewing&amp;apos;s sarcoma, primitive peripheral neuroectodermal tumors, peripheral neuroepithelioma, primitive sarcoma of bone, and ectomesenchymoma.</div>
<div class="sdl4">  </div>
<div class="sdl4">  Confirmed presence of tumor-specific infusion protein by documented RT-PCR which corresponds to one of the tumor specific peptides available for vaccination.</div>
<div class="sdl4">  </div>
<div class="sdl4">  Measurable tumor.</div>
<div class="sdl4">  </div>
<div class="sdl4">  No prior or current CNS metastases.</div>
<div class="sdl4">  </div>
<div class="sdl4">  PRIOR/CONCURRENT THERAPY:</div>
<div class="sdl4">  </div>
<div class="sdl4">  Arm A patients:</div>
<div class="sdl4">  </div>
<div class="sdl4">  May be enrolled on the protocol for the first phase in the absence of RT PCR documentation of a tumor-specific fusion protein which corresponds to one of the tumor-specific peptides available for vaccination.  However, RT PCR documentation at the time of tumor recurrence must occur prior to administration of immunotherapy. At time of initial tumor diagnosis, prior to any cytoreductive therapy.</div>
<div class="sdl4">  </div>
<div class="sdl4">  Arm B patients:</div>
<div class="sdl4">  </div>
<div class="sdl4">  Tumor recurrence occurring during or after receiving at least first line cytoreductive therapy for ESFT and AR.  No more than two post-recurrence salvage regimens unless peripheral CD4+T  cell number is greater than 400 cells per millimeter cubed.</div>
<div class="sdl4">  </div>
<div class="sdl4">  At least 6 weeks since any treatments and recovered from all acute toxic effects from time in which immunotherapy will be started for this study.</div>
<div class="sdl4">  </div>
<div class="sdl4">  No concurrent estrogen therapy during immunotherapy section of study.</div>
<div class="sdl4">  </div>
<div class="sdl4">  PATIENT CHARACTERISTICS:</div>
<div class="sdl4">  </div>
<div class="sdl4">  Age:  2-25 (at time of initial diagnosis of alveolar rhabdomyosarcoma).</div>
<div class="sdl4">  </div>
<div class="sdl4">  Weight:  Greater than 15 kg (at time of apheresis).</div>
<div class="sdl4">  </div>
<div class="sdl4">  Performance status:  ECOG 0-2.</div>
<div class="sdl4">  </div>
<div class="sdl4">  Life expectancy:  At least 8 weeks.</div>
<div class="sdl4">  </div>
<div class="sdl4">  Hematopoietic:</div>
<div class="sdl4">  </div>
<div class="sdl4">  ANC greater than 100,000/mm3.</div>
<div class="sdl4">  </div>
<div class="sdl4">  Hemoglobin greater than 9.0 g/dL.</div>
<div class="sdl4">  </div>
<div class="sdl4">  Platelet count greater than 50,000/mm3.</div>
<div class="sdl4">  </div>
<div class="sdl4">  Hepatic:</div>
<div class="sdl4">  </div>
<div class="sdl4">  Bilirubin less than 2.0 mg/dL (unless related to involvement by tumor).</div>
<div class="sdl4">  </div>
<div class="sdl4">  Transaminases less than 3 times normal (unless related to involvement by tumor).</div>
<div class="sdl4">  </div>
<div class="sdl4">  Renal:</div>
<div class="sdl4">  </div>
<div class="sdl4">  Creatinine less than 1.5 mg/dL or creatinine clearance greater than 60 mL/min.</div>
<div class="sdl4">  </div>
<div class="sdl4">  Cardiovascular:</div>
<div class="sdl4">  </div>
<div class="sdl4">  No major disorder of cardiovascular system.</div>
<div class="sdl4">  </div>
<div class="sdl4">  Cardiac ejection fraction greater than 40%.</div>
<div class="sdl4">  </div>
<div class="sdl4">  Pulmonary:</div>
<div class="sdl4">  </div>
<div class="sdl4">  No major disorder of pulmonary system.</div>
<div class="sdl4">  </div>
<div class="sdl4">  Other:</div>
<div class="sdl4">  </div>
<div class="sdl4">  Not pregnant or nursing.</div>
<div class="sdl4">  </div>
<div class="sdl4">  HIV negative.</div>
<div class="sdl4">  </div>
<div class="sdl4">  Hepatitis B or C negative.</div>
<div class="sdl4">  </div>
<div class="sdl4">  No patients requiring daily oral corticosteroid therapy.</div>
<div class="sdl4">  </div>
<div class="sdl4">  If allergic to eggs, egg products, or thimerosal, or have a history of Guillain-Barre syndrome, ineligible to receive influenza vaccine.</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/criteria&gt;</div>
<div class="sdl2 sds">&lt;healthy_volunteers&gt;</div>
<div class="sdl3">  No</div>
<div class="sdl2 sdz">&lt;/healthy_volunteers&gt;</div>
<div class="sdl2 sds">&lt;patients&gt;</div>
<div class="sdl2 sdz">&lt;/patients&gt;</div>
<div class="sdl2 sds">&lt;expected_enrollment&gt;</div>
<div class="sdl3">  150</div>
<div class="sdl2 sdz">&lt;/expected_enrollment&gt;</div>
<div class="sdl2 sds">&lt;gender&gt;</div>
<div class="sdl3">  Both</div>
<div class="sdl2 sdz">&lt;/gender&gt;</div>
</div><div class="sdl2 sds">&lt;minimum_age&gt;</div>
</td>
<td class="sdiff-b"><img id="sdiff-collapse-f0B-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-f0&#39;)" style="display:none" /><img id="sdiff-collapse-f0B-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f0&#39;)" style="display:none" /><div class="sdl0 sds">&lt;clinical_study&gt;</div>
<div id="sdiff-collapse-f0B-cdiv" class="sdiff-collapsed" title="The middle 214 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f0&#39;)" style="display:none"></div><div id="sdiff-collapse-f0B-ediv" class="sdiff-expanded"><div class="sdl1 sds">&lt;study_id&gt;</div>
<div class="sdl2 sds">&lt;org_name&gt;</div>
<div class="sdl3">  NIHCC</div>
<div class="sdl2 sdz">&lt;/org_name&gt;</div>
<div class="sdl2 sds">&lt;org_full_name&gt;</div>
<div class="sdl3">  National Institutes of Health Clinical Center (CC)</div>
<div class="sdl2 sdz">&lt;/org_full_name&gt;</div>
<div class="sdl2 sds">&lt;org_study_id&gt;</div>
<div class="sdl3">  920210</div>
<div class="sdl2 sdz">&lt;/org_study_id&gt;</div>
<div class="sdl2 sds">&lt;secondary_id&gt;</div>
<div class="sdl3">  92-C-0210</div>
<div class="sdl2 sdz">&lt;/secondary_id&gt;</div>
<div class="sdl2 sds">&lt;nct_id&gt;</div>
<div class="sdl3">  NCT00001300</div>
<div class="sdl2 sdz">&lt;/nct_id&gt;</div>
<div class="sdl1 sdz">&lt;/study_id&gt;</div>
<div class="sdl1 sds">&lt;brief_title&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl3">  A Randomized Study of the Effect of Adjuvant Chemotherapy With Doxorubicin and Ifosfamide With Mesna in the Treatment of High-Grade Adult Extremity Soft Tissue Sarcoma</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/brief_title&gt;</div>
<div class="sdl1 sds">&lt;official_title&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl3">  A Randomized Study of the Effect of Adjuvant Chemotherapy With Doxorubicin and Ifosfamide With Mesna in the Treatment of High-Grade Adult Extremity Soft Tissue Sarcoma</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/official_title&gt;</div>
<div class="sdl1 sds">&lt;study_sponsor&gt;</div>
<div class="sdl2 sds">&lt;lead_sponsor&gt;</div>
<div class="sdl3 sds">&lt;agency&gt;</div>
<div class="sdl4">  National Cancer Institute (NCI)</div>
<div class="sdl3 sdz">&lt;/agency&gt;</div>
<div class="sdl2 sdz">&lt;/lead_sponsor&gt;</div>
<div class="sdl1 sdz">&lt;/study_sponsor&gt;</div>
<div class="sdl1 sds">&lt;oversight_info&gt;</div>
<div class="sdl1 sdz">&lt;/oversight_info&gt;</div>
<div class="sdl1 sds">&lt;brief_summary&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl3">  Randomized study.  All patients must be randomized to treatment on Arms I and II within 3 months of definitive surgery on Regimen A.</div>
<div class="sdl3">  </div>
<div class="sdl3">  </div>
<div class="sdl3">        Regimen A:  Surgery followed, as indicated, by Radiotherapy.  Amputation; or limb-sparing resection followed by involved-field irradiation using megavoltage equipment with or without electron boost.</div>
<div class="sdl3">  </div>
<div class="sdl3">  </div>
<div class="sdl3">        Arm I:  2-Drug Combination Chemotherapy with Hematologic Toxicity Attenuation and Urothelial Protection.  Doxorubicin, DOX, NSC-123127; Ifosfamide, IFF, NSC-109724; with Granulocyte Colony Stimulating Factor (Amgen), G-CSF,</div>
<div class="sdl3">  </div>
<div class="sdl3">  </div>
<div class="sdl3">        NSC-614629; and Mesna, NSC-113891.</div>
<div class="sdl3">  </div>
<div class="sdl3">  </div>
<div class="sdl3">        Arm II:  Observation.  No adjuvant chemotherapy.</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/brief_summary&gt;</div>
<div class="sdl1 sds">&lt;detailed_descr&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl3">  Patients with primary, high-grade soft tissue sarcoma of the extremities will undergo treatment of their primary tumor with either amputation or limb-sparing surgery and radiotherapy, and then be randomized to either observation or adjuvant treatment with doxorubicin and ifosfamide with mesna (with G-CSF) for five cycles beginning post-operatively.  Local recurrence, disease-free survival and overall survival will be evaluated in this randomized two-arm trial.</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/detailed_descr&gt;</div>
<div class="sdl1 sds">&lt;status_block&gt;</div>
<div class="sdl2 sds">&lt;status&gt;</div>
<div class="sdl3">  Completed</div>
<div class="sdl2 sdz">&lt;/status&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl3">  2000-04</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/status_block&gt;</div>
<div class="sdl1 sds">&lt;start_date&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl3">  1992-06</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/start_date&gt;</div>
<div class="sdl1 sds">&lt;end_date&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl3">  2001-03</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/end_date&gt;</div>
<div class="sdl1 sds">&lt;last_follow_up_date&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/last_follow_up_date&gt;</div>
<div class="sdl1 sds">&lt;last_data_entry_date&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/last_data_entry_date&gt;</div>
<div class="sdl1 sds">&lt;phase_block&gt;</div>
<div class="sdl2 sds">&lt;phase&gt;</div>
<div class="sdl3">  Phase 3</div>
<div class="sdl2 sdz">&lt;/phase&gt;</div>
<div class="sdl1 sdz">&lt;/phase_block&gt;</div>
<div class="sdl1 sds">&lt;study_type&gt;</div>
<div class="sdl2">  Interventional</div>
<div class="sdl1 sdz">&lt;/study_type&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Treatment</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Efficacy Study</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  Sarcoma</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;intervention&gt;</div>
<div class="sdl2 sds">&lt;intervent_type&gt;</div>
<div class="sdl3">  Drug</div>
<div class="sdl2 sdz">&lt;/intervent_type&gt;</div>
<div class="sdl2 sds">&lt;primary_name&gt;</div>
<div class="sdl3">  doxorubicin</div>
<div class="sdl2 sdz">&lt;/primary_name&gt;</div>
<div class="sdl1 sdz">&lt;/intervention&gt;</div>
<div class="sdl1 sds">&lt;intervention&gt;</div>
<div class="sdl2 sds">&lt;intervent_type&gt;</div>
<div class="sdl3">  Drug</div>
<div class="sdl2 sdz">&lt;/intervent_type&gt;</div>
<div class="sdl2 sds">&lt;primary_name&gt;</div>
<div class="sdl3">  ifosfamide</div>
<div class="sdl2 sdz">&lt;/primary_name&gt;</div>
<div class="sdl1 sdz">&lt;/intervention&gt;</div>
<div class="sdl1 sds">&lt;intervention&gt;</div>
<div class="sdl2 sds">&lt;intervent_type&gt;</div>
<div class="sdl3">  Drug</div>
<div class="sdl2 sdz">&lt;/intervent_type&gt;</div>
<div class="sdl2 sds">&lt;primary_name&gt;</div>
<div class="sdl3">  mesna</div>
<div class="sdl2 sdz">&lt;/primary_name&gt;</div>
<div class="sdl1 sdz">&lt;/intervention&gt;</div>
<div class="sdl1 sds">&lt;eligibility&gt;</div>
<div class="sdl2 sds">&lt;criteria&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  DISEASE CHARACTERISTICS:</div>
<div class="sdl4">  </div>
<div class="sdl4">  Histologically proven AR and ESFT which includes: Classical, atypical and extraosseous Ewing&amp;apos;s sarcoma, primitive peripheral neuroectodermal tumors, peripheral neuroepithelioma, primitive sarcoma of bone, and ectomesenchymoma.</div>
<div class="sdl4">  </div>
<div class="sdl4">  Confirmed presence of tumor-specific infusion protein by documented RT-PCR which corresponds to one of the tumor specific peptides available for vaccination.</div>
<div class="sdl4">  </div>
<div class="sdl4">  Measurable tumor.</div>
<div class="sdl4">  </div>
<div class="sdl4">  No prior or current CNS metastases.</div>
<div class="sdl4">  </div>
<div class="sdl4">  PRIOR/CONCURRENT THERAPY:</div>
<div class="sdl4">  </div>
<div class="sdl4">  Arm A patients:</div>
<div class="sdl4">  </div>
<div class="sdl4">  May be enrolled on the protocol for the first phase in the absence of RT PCR documentation of a tumor-specific fusion protein which corresponds to one of the tumor-specific peptides available for vaccination.  However, RT PCR documentation at the time of tumor recurrence must occur prior to administration of immunotherapy. At time of initial tumor diagnosis, prior to any cytoreductive therapy.</div>
<div class="sdl4">  </div>
<div class="sdl4">  Arm B patients:</div>
<div class="sdl4">  </div>
<div class="sdl4">  Tumor recurrence occurring during or after receiving at least first line cytoreductive therapy for ESFT and AR.  No more than two post-recurrence salvage regimens unless peripheral CD4+T  cell number is greater than 400 cells per millimeter cubed.</div>
<div class="sdl4">  </div>
<div class="sdl4">  At least 6 weeks since any treatments and recovered from all acute toxic effects from time in which immunotherapy will be started for this study.</div>
<div class="sdl4">  </div>
<div class="sdl4">  No concurrent estrogen therapy during immunotherapy section of study.</div>
<div class="sdl4">  </div>
<div class="sdl4">  PATIENT CHARACTERISTICS:</div>
<div class="sdl4">  </div>
<div class="sdl4">  Age:  2-25 (at time of initial diagnosis of alveolar rhabdomyosarcoma).</div>
<div class="sdl4">  </div>
<div class="sdl4">  Weight:  Greater than 15 kg (at time of apheresis).</div>
<div class="sdl4">  </div>
<div class="sdl4">  Performance status:  ECOG 0-2.</div>
<div class="sdl4">  </div>
<div class="sdl4">  Life expectancy:  At least 8 weeks.</div>
<div class="sdl4">  </div>
<div class="sdl4">  Hematopoietic:</div>
<div class="sdl4">  </div>
<div class="sdl4">  ANC greater than 100,000/mm3.</div>
<div class="sdl4">  </div>
<div class="sdl4">  Hemoglobin greater than 9.0 g/dL.</div>
<div class="sdl4">  </div>
<div class="sdl4">  Platelet count greater than 50,000/mm3.</div>
<div class="sdl4">  </div>
<div class="sdl4">  Hepatic:</div>
<div class="sdl4">  </div>
<div class="sdl4">  Bilirubin less than 2.0 mg/dL (unless related to involvement by tumor).</div>
<div class="sdl4">  </div>
<div class="sdl4">  Transaminases less than 3 times normal (unless related to involvement by tumor).</div>
<div class="sdl4">  </div>
<div class="sdl4">  Renal:</div>
<div class="sdl4">  </div>
<div class="sdl4">  Creatinine less than 1.5 mg/dL or creatinine clearance greater than 60 mL/min.</div>
<div class="sdl4">  </div>
<div class="sdl4">  Cardiovascular:</div>
<div class="sdl4">  </div>
<div class="sdl4">  No major disorder of cardiovascular system.</div>
<div class="sdl4">  </div>
<div class="sdl4">  Cardiac ejection fraction greater than 40%.</div>
<div class="sdl4">  </div>
<div class="sdl4">  Pulmonary:</div>
<div class="sdl4">  </div>
<div class="sdl4">  No major disorder of pulmonary system.</div>
<div class="sdl4">  </div>
<div class="sdl4">  Other:</div>
<div class="sdl4">  </div>
<div class="sdl4">  Not pregnant or nursing.</div>
<div class="sdl4">  </div>
<div class="sdl4">  HIV negative.</div>
<div class="sdl4">  </div>
<div class="sdl4">  Hepatitis B or C negative.</div>
<div class="sdl4">  </div>
<div class="sdl4">  No patients requiring daily oral corticosteroid therapy.</div>
<div class="sdl4">  </div>
<div class="sdl4">  If allergic to eggs, egg products, or thimerosal, or have a history of Guillain-Barre syndrome, ineligible to receive influenza vaccine.</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/criteria&gt;</div>
<div class="sdl2 sds">&lt;healthy_volunteers&gt;</div>
<div class="sdl3">  No</div>
<div class="sdl2 sdz">&lt;/healthy_volunteers&gt;</div>
<div class="sdl2 sds">&lt;patients&gt;</div>
<div class="sdl2 sdz">&lt;/patients&gt;</div>
<div class="sdl2 sds">&lt;expected_enrollment&gt;</div>
<div class="sdl3">  150</div>
<div class="sdl2 sdz">&lt;/expected_enrollment&gt;</div>
<div class="sdl2 sds">&lt;gender&gt;</div>
<div class="sdl3">  Both</div>
<div class="sdl2 sdz">&lt;/gender&gt;</div>
</div><div class="sdl2 sds">&lt;minimum_age&gt;</div>
</td>
</tr>
<tr class="sdiff-del" id="sdiff-chunk-f2"><td class="sdiff-h">2</td>
<td class="sdiff-a"><div class="sdl3">  N/A</div>
</td>
<td class="sdiff-b"><div class="sdl3"></div>
</td>
</tr>
<tr class="sdiff-unc" id="sdiff-chunk-f3"><td class="sdiff-h">3</td>
<td class="sdiff-a"><div class="sdl2 sdz">&lt;/minimum_age&gt;</div>
<div class="sdl2 sds">&lt;maximum_age&gt;</div>
</td>
<td class="sdiff-b"><div class="sdl2 sdz">&lt;/minimum_age&gt;</div>
<div class="sdl2 sds">&lt;maximum_age&gt;</div>
</td>
</tr>
<tr class="sdiff-del" id="sdiff-chunk-f4"><td class="sdiff-h">4</td>
<td class="sdiff-a"><div class="sdl3">  N/A</div>
</td>
<td class="sdiff-b"><div class="sdl3"></div>
</td>
</tr>
<tr class="sdiff-unc" id="sdiff-chunk-f5"><td class="sdiff-h">5</td>
<td class="sdiff-a"><img id="sdiff-collapse-f220A-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-f220&#39;)" style="display:none" /><img id="sdiff-collapse-f220A-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f220&#39;)" style="display:none" /><div class="sdl2 sdz">&lt;/maximum_age&gt;</div>
<div id="sdiff-collapse-f220A-cdiv" class="sdiff-collapsed" title="The middle 62 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f220&#39;)" style="display:none"></div><div id="sdiff-collapse-f220A-ediv" class="sdiff-expanded"><div class="sdl1 sdz">&lt;/eligibility&gt;</div>
<div class="sdl1 sds">&lt;location&gt;</div>
<div class="sdl2 sds">&lt;facility&gt;</div>
<div class="sdl3 sds">&lt;name&gt;</div>
<div class="sdl4">  National Cancer Institute (NCI)</div>
<div class="sdl3 sdz">&lt;/name&gt;</div>
<div class="sdl3 sds">&lt;address&gt;</div>
<div class="sdl4 sds">&lt;city&gt;</div>
<div class="sdl5">  Bethesda</div>
<div class="sdl4 sdz">&lt;/city&gt;</div>
<div class="sdl4 sds">&lt;state&gt;</div>
<div class="sdl5">  Maryland</div>
<div class="sdl4 sdz">&lt;/state&gt;</div>
<div class="sdl4 sds">&lt;zip&gt;</div>
<div class="sdl5">  20892</div>
<div class="sdl4 sdz">&lt;/zip&gt;</div>
<div class="sdl4 sds">&lt;country&gt;</div>
<div class="sdl5">  United States</div>
<div class="sdl4 sdz">&lt;/country&gt;</div>
<div class="sdl3 sdz">&lt;/address&gt;</div>
<div class="sdl2 sdz">&lt;/facility&gt;</div>
<div class="sdl2 sds">&lt;status&gt;</div>
<div class="sdl2 sdz">&lt;/status&gt;</div>
<div class="sdl1 sdz">&lt;/location&gt;</div>
<div class="sdl1 sds">&lt;background&gt;</div>
<div class="sdl2 sds">&lt;reference&gt;</div>
<div class="sdl3 sds">&lt;citation&gt;</div>
<div class="sdl4">  Lawrence W Jr, Donegan WL, Natarajan N, Mettlin C, Beart R, Winchester D.  Adult soft tissue sarcomas. A pattern of care survey of the American College of Surgeons. Ann Surg. 1987 Apr;205(4):349-59.</div>
<div class="sdl3 sdz">&lt;/citation&gt;</div>
<div class="sdl3 sds">&lt;medline_ui&gt;</div>
<div class="sdl4">  3566372</div>
<div class="sdl3 sdz">&lt;/medline_ui&gt;</div>
<div class="sdl2 sdz">&lt;/reference&gt;</div>
<div class="sdl2 sds">&lt;reference&gt;</div>
<div class="sdl3 sds">&lt;citation&gt;</div>
<div class="sdl4">  Alvegard TA, Sigurdsson H, Mouridsen H, Solheim O, Unsgaard B, Ringborg U, Dahl O, Nordentoft AM, Blomqvist C, Rydholm A, et al.  Adjuvant chemotherapy with doxorubicin in high-grade soft tissue sarcoma: a randomized trial of the Scandinavian Sarcoma Group. J Clin Oncol. 1989 Oct;7(10):1504-13.</div>
<div class="sdl3 sdz">&lt;/citation&gt;</div>
<div class="sdl3 sds">&lt;medline_ui&gt;</div>
<div class="sdl4">  2674336</div>
<div class="sdl3 sdz">&lt;/medline_ui&gt;</div>
<div class="sdl2 sdz">&lt;/reference&gt;</div>
<div class="sdl2 sds">&lt;reference&gt;</div>
<div class="sdl3 sds">&lt;citation&gt;</div>
<div class="sdl4">  Chang AE, Kinsella T, Glatstein E, Baker AR, Sindelar WF, Lotze MT, Danforth DN Jr, Sugarbaker PH, Lack EE, Steinberg SM, et al.  Adjuvant chemotherapy for patients with high-grade soft-tissue sarcomas of the extremity. J Clin Oncol. 1988 Sep;6(9):1491-500.</div>
<div class="sdl3 sdz">&lt;/citation&gt;</div>
<div class="sdl3 sds">&lt;medline_ui&gt;</div>
<div class="sdl4">  3047339</div>
<div class="sdl3 sdz">&lt;/medline_ui&gt;</div>
<div class="sdl2 sdz">&lt;/reference&gt;</div>
<div class="sdl1 sdz">&lt;/background&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  Adjuvant Chemotherapy</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  Ifosfamide</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  Randomized Study</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  Soft Tissue Sarcoma</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
</div><div class="sdl1 sds">&lt;initial_release_date&gt;</div>
</td>
<td class="sdiff-b"><img id="sdiff-collapse-f220B-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-f220&#39;)" style="display:none" /><img id="sdiff-collapse-f220B-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f220&#39;)" style="display:none" /><div class="sdl2 sdz">&lt;/maximum_age&gt;</div>
<div id="sdiff-collapse-f220B-cdiv" class="sdiff-collapsed" title="The middle 62 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f220&#39;)" style="display:none"></div><div id="sdiff-collapse-f220B-ediv" class="sdiff-expanded"><div class="sdl1 sdz">&lt;/eligibility&gt;</div>
<div class="sdl1 sds">&lt;location&gt;</div>
<div class="sdl2 sds">&lt;facility&gt;</div>
<div class="sdl3 sds">&lt;name&gt;</div>
<div class="sdl4">  National Cancer Institute (NCI)</div>
<div class="sdl3 sdz">&lt;/name&gt;</div>
<div class="sdl3 sds">&lt;address&gt;</div>
<div class="sdl4 sds">&lt;city&gt;</div>
<div class="sdl5">  Bethesda</div>
<div class="sdl4 sdz">&lt;/city&gt;</div>
<div class="sdl4 sds">&lt;state&gt;</div>
<div class="sdl5">  Maryland</div>
<div class="sdl4 sdz">&lt;/state&gt;</div>
<div class="sdl4 sds">&lt;zip&gt;</div>
<div class="sdl5">  20892</div>
<div class="sdl4 sdz">&lt;/zip&gt;</div>
<div class="sdl4 sds">&lt;country&gt;</div>
<div class="sdl5">  United States</div>
<div class="sdl4 sdz">&lt;/country&gt;</div>
<div class="sdl3 sdz">&lt;/address&gt;</div>
<div class="sdl2 sdz">&lt;/facility&gt;</div>
<div class="sdl2 sds">&lt;status&gt;</div>
<div class="sdl2 sdz">&lt;/status&gt;</div>
<div class="sdl1 sdz">&lt;/location&gt;</div>
<div class="sdl1 sds">&lt;background&gt;</div>
<div class="sdl2 sds">&lt;reference&gt;</div>
<div class="sdl3 sds">&lt;citation&gt;</div>
<div class="sdl4">  Lawrence W Jr, Donegan WL, Natarajan N, Mettlin C, Beart R, Winchester D.  Adult soft tissue sarcomas. A pattern of care survey of the American College of Surgeons. Ann Surg. 1987 Apr;205(4):349-59.</div>
<div class="sdl3 sdz">&lt;/citation&gt;</div>
<div class="sdl3 sds">&lt;medline_ui&gt;</div>
<div class="sdl4">  3566372</div>
<div class="sdl3 sdz">&lt;/medline_ui&gt;</div>
<div class="sdl2 sdz">&lt;/reference&gt;</div>
<div class="sdl2 sds">&lt;reference&gt;</div>
<div class="sdl3 sds">&lt;citation&gt;</div>
<div class="sdl4">  Alvegard TA, Sigurdsson H, Mouridsen H, Solheim O, Unsgaard B, Ringborg U, Dahl O, Nordentoft AM, Blomqvist C, Rydholm A, et al.  Adjuvant chemotherapy with doxorubicin in high-grade soft tissue sarcoma: a randomized trial of the Scandinavian Sarcoma Group. J Clin Oncol. 1989 Oct;7(10):1504-13.</div>
<div class="sdl3 sdz">&lt;/citation&gt;</div>
<div class="sdl3 sds">&lt;medline_ui&gt;</div>
<div class="sdl4">  2674336</div>
<div class="sdl3 sdz">&lt;/medline_ui&gt;</div>
<div class="sdl2 sdz">&lt;/reference&gt;</div>
<div class="sdl2 sds">&lt;reference&gt;</div>
<div class="sdl3 sds">&lt;citation&gt;</div>
<div class="sdl4">  Chang AE, Kinsella T, Glatstein E, Baker AR, Sindelar WF, Lotze MT, Danforth DN Jr, Sugarbaker PH, Lack EE, Steinberg SM, et al.  Adjuvant chemotherapy for patients with high-grade soft-tissue sarcomas of the extremity. J Clin Oncol. 1988 Sep;6(9):1491-500.</div>
<div class="sdl3 sdz">&lt;/citation&gt;</div>
<div class="sdl3 sds">&lt;medline_ui&gt;</div>
<div class="sdl4">  3047339</div>
<div class="sdl3 sdz">&lt;/medline_ui&gt;</div>
<div class="sdl2 sdz">&lt;/reference&gt;</div>
<div class="sdl1 sdz">&lt;/background&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  Adjuvant Chemotherapy</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  Ifosfamide</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  Randomized Study</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  Soft Tissue Sarcoma</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
</div><div class="sdl1 sds">&lt;initial_release_date&gt;</div>
</td>
</tr>
<tr class="sdiff-chg" id="sdiff-chunk-f6"><td class="sdiff-h">6</td>
<td class="sdiff-a"><div class="sdl2"><span class="sdwc">2006-07-14</span> </div>
</td>
<td class="sdiff-b"><div class="sdl2"><span class="sdwc">1999-11-03</span> </div>
</td>
</tr>
<tr class="sdiff-unc" id="sdiff-chunk-f7"><td class="sdiff-h">7</td>
<td class="sdiff-a"><img id="sdiff-collapse-f285A-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-f285&#39;)" style="display:none" /><img id="sdiff-collapse-f285A-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f285&#39;)" style="display:none" /><div class="sdl1 sdz">&lt;/initial_release_date&gt;</div>
<div id="sdiff-collapse-f285A-cdiv" class="sdiff-collapsed" title="The middle 3 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f285&#39;)" style="display:none"></div><div id="sdiff-collapse-f285A-ediv" class="sdiff-expanded"><div class="sdl1 sds">&lt;last_release_date&gt;</div>
<div class="sdl2">  2006-07-14</div>
<div class="sdl1 sdz">&lt;/last_release_date&gt;</div>
</div><div class="sdl0 sdz">&lt;/clinical_study&gt;</div>
</td>
<td class="sdiff-b"><img id="sdiff-collapse-f285B-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-f285&#39;)" style="display:none" /><img id="sdiff-collapse-f285B-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f285&#39;)" style="display:none" /><div class="sdl1 sdz">&lt;/initial_release_date&gt;</div>
<div id="sdiff-collapse-f285B-cdiv" class="sdiff-collapsed" title="The middle 3 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f285&#39;)" style="display:none"></div><div id="sdiff-collapse-f285B-ediv" class="sdiff-expanded"><div class="sdl1 sds">&lt;last_release_date&gt;</div>
<div class="sdl2">  2006-07-14</div>
<div class="sdl1 sdz">&lt;/last_release_date&gt;</div>
</div><div class="sdl0 sdz">&lt;/clinical_study&gt;</div>
</td>
</tr>

</table></div><div class="sdiff-view" id="sdiff-main" style="display: block"><table class="sdiff navLinks"><colgroup><col id="h-col" /><col id="a-col" /><col id="b-col" /></colgroup><tr><th class="sdiff-h" /><th class="sdiff-a"><div class="sdiff-prev"><a href="/archive/NCT00001300/2006_07_14/changes" title="Show changes from prior version to this one"><img src="/archive/prev.gif" alt="[Previous]" width="23" height="19" /></a></div><h2>Before</h2><h3><a href="/archive/NCT00001300/2006_07_14">(Updated 2006_07_14)</a></h3></th><th class="sdiff-b"><div class="sdiff-next"><a href="/archive/NCT00001300/2008_03_03/changes" title="Show changes from this version to next one"><img src="/archive/next.gif" alt="[Next]" width="23" height="19" /></a></div><h2>After</h2><h3><a href="/archive/NCT00001300/2007_01_22">(Updated 2007_01_22)</a></h3></th></tr>
<tr class="sdiff-unc" id="sdiff-chunk-m1"><td class="sdiff-h">1</td>
<td class="sdiff-a"><img id="sdiff-collapse-m0A-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-m0&#39;)" style="display:none" /><img id="sdiff-collapse-m0A-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m0&#39;)" style="display:none" /><div class="sdl0 sds">&lt;clinical_study&gt;</div>
<div id="sdiff-collapse-m0A-cdiv" class="sdiff-collapsed" title="The middle 214 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m0&#39;)" style="display:none"></div><div id="sdiff-collapse-m0A-ediv" class="sdiff-expanded"><div class="sdl1 sds">&lt;study_id&gt;</div>
<div class="sdl2 sds">&lt;org_name&gt;</div>
<div class="sdl3">  NIHCC</div>
<div class="sdl2 sdz">&lt;/org_name&gt;</div>
<div class="sdl2 sds">&lt;org_full_name&gt;</div>
<div class="sdl3">  National Institutes of Health Clinical Center (CC)</div>
<div class="sdl2 sdz">&lt;/org_full_name&gt;</div>
<div class="sdl2 sds">&lt;org_study_id&gt;</div>
<div class="sdl3">  920210</div>
<div class="sdl2 sdz">&lt;/org_study_id&gt;</div>
<div class="sdl2 sds">&lt;secondary_id&gt;</div>
<div class="sdl3">  92-C-0210</div>
<div class="sdl2 sdz">&lt;/secondary_id&gt;</div>
<div class="sdl2 sds">&lt;nct_id&gt;</div>
<div class="sdl3">  NCT00001300</div>
<div class="sdl2 sdz">&lt;/nct_id&gt;</div>
<div class="sdl1 sdz">&lt;/study_id&gt;</div>
<div class="sdl1 sds">&lt;brief_title&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl3">  A Randomized Study of the Effect of Adjuvant Chemotherapy With Doxorubicin and Ifosfamide With Mesna in the Treatment of High-Grade Adult Extremity Soft Tissue Sarcoma</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/brief_title&gt;</div>
<div class="sdl1 sds">&lt;official_title&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl3">  A Randomized Study of the Effect of Adjuvant Chemotherapy With Doxorubicin and Ifosfamide With Mesna in the Treatment of High-Grade Adult Extremity Soft Tissue Sarcoma</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/official_title&gt;</div>
<div class="sdl1 sds">&lt;study_sponsor&gt;</div>
<div class="sdl2 sds">&lt;lead_sponsor&gt;</div>
<div class="sdl3 sds">&lt;agency&gt;</div>
<div class="sdl4">  National Cancer Institute (NCI)</div>
<div class="sdl3 sdz">&lt;/agency&gt;</div>
<div class="sdl2 sdz">&lt;/lead_sponsor&gt;</div>
<div class="sdl1 sdz">&lt;/study_sponsor&gt;</div>
<div class="sdl1 sds">&lt;oversight_info&gt;</div>
<div class="sdl1 sdz">&lt;/oversight_info&gt;</div>
<div class="sdl1 sds">&lt;brief_summary&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl3">  Randomized study.  All patients must be randomized to treatment on Arms I and II within 3 months of definitive surgery on Regimen A.</div>
<div class="sdl3">  </div>
<div class="sdl3">  </div>
<div class="sdl3">        Regimen A:  Surgery followed, as indicated, by Radiotherapy.  Amputation; or limb-sparing resection followed by involved-field irradiation using megavoltage equipment with or without electron boost.</div>
<div class="sdl3">  </div>
<div class="sdl3">  </div>
<div class="sdl3">        Arm I:  2-Drug Combination Chemotherapy with Hematologic Toxicity Attenuation and Urothelial Protection.  Doxorubicin, DOX, NSC-123127; Ifosfamide, IFF, NSC-109724; with Granulocyte Colony Stimulating Factor (Amgen), G-CSF,</div>
<div class="sdl3">  </div>
<div class="sdl3">  </div>
<div class="sdl3">        NSC-614629; and Mesna, NSC-113891.</div>
<div class="sdl3">  </div>
<div class="sdl3">  </div>
<div class="sdl3">        Arm II:  Observation.  No adjuvant chemotherapy.</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/brief_summary&gt;</div>
<div class="sdl1 sds">&lt;detailed_descr&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl3">  Patients with primary, high-grade soft tissue sarcoma of the extremities will undergo treatment of their primary tumor with either amputation or limb-sparing surgery and radiotherapy, and then be randomized to either observation or adjuvant treatment with doxorubicin and ifosfamide with mesna (with G-CSF) for five cycles beginning post-operatively.  Local recurrence, disease-free survival and overall survival will be evaluated in this randomized two-arm trial.</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/detailed_descr&gt;</div>
<div class="sdl1 sds">&lt;status_block&gt;</div>
<div class="sdl2 sds">&lt;status&gt;</div>
<div class="sdl3">  Completed</div>
<div class="sdl2 sdz">&lt;/status&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl3">  2000-04</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/status_block&gt;</div>
<div class="sdl1 sds">&lt;start_date&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl3">  1992-06</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/start_date&gt;</div>
<div class="sdl1 sds">&lt;end_date&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl3">  2001-03</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/end_date&gt;</div>
<div class="sdl1 sds">&lt;last_follow_up_date&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/last_follow_up_date&gt;</div>
<div class="sdl1 sds">&lt;last_data_entry_date&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/last_data_entry_date&gt;</div>
<div class="sdl1 sds">&lt;phase_block&gt;</div>
<div class="sdl2 sds">&lt;phase&gt;</div>
<div class="sdl3">  Phase 3</div>
<div class="sdl2 sdz">&lt;/phase&gt;</div>
<div class="sdl1 sdz">&lt;/phase_block&gt;</div>
<div class="sdl1 sds">&lt;study_type&gt;</div>
<div class="sdl2">  Interventional</div>
<div class="sdl1 sdz">&lt;/study_type&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Treatment</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Efficacy Study</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  Sarcoma</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;intervention&gt;</div>
<div class="sdl2 sds">&lt;intervent_type&gt;</div>
<div class="sdl3">  Drug</div>
<div class="sdl2 sdz">&lt;/intervent_type&gt;</div>
<div class="sdl2 sds">&lt;primary_name&gt;</div>
<div class="sdl3">  doxorubicin</div>
<div class="sdl2 sdz">&lt;/primary_name&gt;</div>
<div class="sdl1 sdz">&lt;/intervention&gt;</div>
<div class="sdl1 sds">&lt;intervention&gt;</div>
<div class="sdl2 sds">&lt;intervent_type&gt;</div>
<div class="sdl3">  Drug</div>
<div class="sdl2 sdz">&lt;/intervent_type&gt;</div>
<div class="sdl2 sds">&lt;primary_name&gt;</div>
<div class="sdl3">  ifosfamide</div>
<div class="sdl2 sdz">&lt;/primary_name&gt;</div>
<div class="sdl1 sdz">&lt;/intervention&gt;</div>
<div class="sdl1 sds">&lt;intervention&gt;</div>
<div class="sdl2 sds">&lt;intervent_type&gt;</div>
<div class="sdl3">  Drug</div>
<div class="sdl2 sdz">&lt;/intervent_type&gt;</div>
<div class="sdl2 sds">&lt;primary_name&gt;</div>
<div class="sdl3">  mesna</div>
<div class="sdl2 sdz">&lt;/primary_name&gt;</div>
<div class="sdl1 sdz">&lt;/intervention&gt;</div>
<div class="sdl1 sds">&lt;eligibility&gt;</div>
<div class="sdl2 sds">&lt;criteria&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  DISEASE CHARACTERISTICS:</div>
<div class="sdl4">  </div>
<div class="sdl4">  Histologically proven AR and ESFT which includes: Classical, atypical and extraosseous Ewing&amp;apos;s sarcoma, primitive peripheral neuroectodermal tumors, peripheral neuroepithelioma, primitive sarcoma of bone, and ectomesenchymoma.</div>
<div class="sdl4">  </div>
<div class="sdl4">  Confirmed presence of tumor-specific infusion protein by documented RT-PCR which corresponds to one of the tumor specific peptides available for vaccination.</div>
<div class="sdl4">  </div>
<div class="sdl4">  Measurable tumor.</div>
<div class="sdl4">  </div>
<div class="sdl4">  No prior or current CNS metastases.</div>
<div class="sdl4">  </div>
<div class="sdl4">  PRIOR/CONCURRENT THERAPY:</div>
<div class="sdl4">  </div>
<div class="sdl4">  Arm A patients:</div>
<div class="sdl4">  </div>
<div class="sdl4">  May be enrolled on the protocol for the first phase in the absence of RT PCR documentation of a tumor-specific fusion protein which corresponds to one of the tumor-specific peptides available for vaccination.  However, RT PCR documentation at the time of tumor recurrence must occur prior to administration of immunotherapy. At time of initial tumor diagnosis, prior to any cytoreductive therapy.</div>
<div class="sdl4">  </div>
<div class="sdl4">  Arm B patients:</div>
<div class="sdl4">  </div>
<div class="sdl4">  Tumor recurrence occurring during or after receiving at least first line cytoreductive therapy for ESFT and AR.  No more than two post-recurrence salvage regimens unless peripheral CD4+T  cell number is greater than 400 cells per millimeter cubed.</div>
<div class="sdl4">  </div>
<div class="sdl4">  At least 6 weeks since any treatments and recovered from all acute toxic effects from time in which immunotherapy will be started for this study.</div>
<div class="sdl4">  </div>
<div class="sdl4">  No concurrent estrogen therapy during immunotherapy section of study.</div>
<div class="sdl4">  </div>
<div class="sdl4">  PATIENT CHARACTERISTICS:</div>
<div class="sdl4">  </div>
<div class="sdl4">  Age:  2-25 (at time of initial diagnosis of alveolar rhabdomyosarcoma).</div>
<div class="sdl4">  </div>
<div class="sdl4">  Weight:  Greater than 15 kg (at time of apheresis).</div>
<div class="sdl4">  </div>
<div class="sdl4">  Performance status:  ECOG 0-2.</div>
<div class="sdl4">  </div>
<div class="sdl4">  Life expectancy:  At least 8 weeks.</div>
<div class="sdl4">  </div>
<div class="sdl4">  Hematopoietic:</div>
<div class="sdl4">  </div>
<div class="sdl4">  ANC greater than 100,000/mm3.</div>
<div class="sdl4">  </div>
<div class="sdl4">  Hemoglobin greater than 9.0 g/dL.</div>
<div class="sdl4">  </div>
<div class="sdl4">  Platelet count greater than 50,000/mm3.</div>
<div class="sdl4">  </div>
<div class="sdl4">  Hepatic:</div>
<div class="sdl4">  </div>
<div class="sdl4">  Bilirubin less than 2.0 mg/dL (unless related to involvement by tumor).</div>
<div class="sdl4">  </div>
<div class="sdl4">  Transaminases less than 3 times normal (unless related to involvement by tumor).</div>
<div class="sdl4">  </div>
<div class="sdl4">  Renal:</div>
<div class="sdl4">  </div>
<div class="sdl4">  Creatinine less than 1.5 mg/dL or creatinine clearance greater than 60 mL/min.</div>
<div class="sdl4">  </div>
<div class="sdl4">  Cardiovascular:</div>
<div class="sdl4">  </div>
<div class="sdl4">  No major disorder of cardiovascular system.</div>
<div class="sdl4">  </div>
<div class="sdl4">  Cardiac ejection fraction greater than 40%.</div>
<div class="sdl4">  </div>
<div class="sdl4">  Pulmonary:</div>
<div class="sdl4">  </div>
<div class="sdl4">  No major disorder of pulmonary system.</div>
<div class="sdl4">  </div>
<div class="sdl4">  Other:</div>
<div class="sdl4">  </div>
<div class="sdl4">  Not pregnant or nursing.</div>
<div class="sdl4">  </div>
<div class="sdl4">  HIV negative.</div>
<div class="sdl4">  </div>
<div class="sdl4">  Hepatitis B or C negative.</div>
<div class="sdl4">  </div>
<div class="sdl4">  No patients requiring daily oral corticosteroid therapy.</div>
<div class="sdl4">  </div>
<div class="sdl4">  If allergic to eggs, egg products, or thimerosal, or have a history of Guillain-Barre syndrome, ineligible to receive influenza vaccine.</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/criteria&gt;</div>
<div class="sdl2 sds">&lt;healthy_volunteers&gt;</div>
<div class="sdl3">  No</div>
<div class="sdl2 sdz">&lt;/healthy_volunteers&gt;</div>
<div class="sdl2 sds">&lt;patients&gt;</div>
<div class="sdl2 sdz">&lt;/patients&gt;</div>
<div class="sdl2 sds">&lt;expected_enrollment&gt;</div>
<div class="sdl3">  150</div>
<div class="sdl2 sdz">&lt;/expected_enrollment&gt;</div>
<div class="sdl2 sds">&lt;gender&gt;</div>
<div class="sdl3">  Both</div>
<div class="sdl2 sdz">&lt;/gender&gt;</div>
</div><div class="sdl2 sds">&lt;minimum_age&gt;</div>
</td>
<td class="sdiff-b"><img id="sdiff-collapse-m0B-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-m0&#39;)" style="display:none" /><img id="sdiff-collapse-m0B-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m0&#39;)" style="display:none" /><div class="sdl0 sds">&lt;clinical_study&gt;</div>
<div id="sdiff-collapse-m0B-cdiv" class="sdiff-collapsed" title="The middle 214 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m0&#39;)" style="display:none"></div><div id="sdiff-collapse-m0B-ediv" class="sdiff-expanded"><div class="sdl1 sds">&lt;study_id&gt;</div>
<div class="sdl2 sds">&lt;org_name&gt;</div>
<div class="sdl3">  NIHCC</div>
<div class="sdl2 sdz">&lt;/org_name&gt;</div>
<div class="sdl2 sds">&lt;org_full_name&gt;</div>
<div class="sdl3">  National Institutes of Health Clinical Center (CC)</div>
<div class="sdl2 sdz">&lt;/org_full_name&gt;</div>
<div class="sdl2 sds">&lt;org_study_id&gt;</div>
<div class="sdl3">  920210</div>
<div class="sdl2 sdz">&lt;/org_study_id&gt;</div>
<div class="sdl2 sds">&lt;secondary_id&gt;</div>
<div class="sdl3">  92-C-0210</div>
<div class="sdl2 sdz">&lt;/secondary_id&gt;</div>
<div class="sdl2 sds">&lt;nct_id&gt;</div>
<div class="sdl3">  NCT00001300</div>
<div class="sdl2 sdz">&lt;/nct_id&gt;</div>
<div class="sdl1 sdz">&lt;/study_id&gt;</div>
<div class="sdl1 sds">&lt;brief_title&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl3">  A Randomized Study of the Effect of Adjuvant Chemotherapy With Doxorubicin and Ifosfamide With Mesna in the Treatment of High-Grade Adult Extremity Soft Tissue Sarcoma</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/brief_title&gt;</div>
<div class="sdl1 sds">&lt;official_title&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl3">  A Randomized Study of the Effect of Adjuvant Chemotherapy With Doxorubicin and Ifosfamide With Mesna in the Treatment of High-Grade Adult Extremity Soft Tissue Sarcoma</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/official_title&gt;</div>
<div class="sdl1 sds">&lt;study_sponsor&gt;</div>
<div class="sdl2 sds">&lt;lead_sponsor&gt;</div>
<div class="sdl3 sds">&lt;agency&gt;</div>
<div class="sdl4">  National Cancer Institute (NCI)</div>
<div class="sdl3 sdz">&lt;/agency&gt;</div>
<div class="sdl2 sdz">&lt;/lead_sponsor&gt;</div>
<div class="sdl1 sdz">&lt;/study_sponsor&gt;</div>
<div class="sdl1 sds">&lt;oversight_info&gt;</div>
<div class="sdl1 sdz">&lt;/oversight_info&gt;</div>
<div class="sdl1 sds">&lt;brief_summary&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl3">  Randomized study.  All patients must be randomized to treatment on Arms I and II within 3 months of definitive surgery on Regimen A.</div>
<div class="sdl3">  </div>
<div class="sdl3">  </div>
<div class="sdl3">        Regimen A:  Surgery followed, as indicated, by Radiotherapy.  Amputation; or limb-sparing resection followed by involved-field irradiation using megavoltage equipment with or without electron boost.</div>
<div class="sdl3">  </div>
<div class="sdl3">  </div>
<div class="sdl3">        Arm I:  2-Drug Combination Chemotherapy with Hematologic Toxicity Attenuation and Urothelial Protection.  Doxorubicin, DOX, NSC-123127; Ifosfamide, IFF, NSC-109724; with Granulocyte Colony Stimulating Factor (Amgen), G-CSF,</div>
<div class="sdl3">  </div>
<div class="sdl3">  </div>
<div class="sdl3">        NSC-614629; and Mesna, NSC-113891.</div>
<div class="sdl3">  </div>
<div class="sdl3">  </div>
<div class="sdl3">        Arm II:  Observation.  No adjuvant chemotherapy.</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/brief_summary&gt;</div>
<div class="sdl1 sds">&lt;detailed_descr&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl3">  Patients with primary, high-grade soft tissue sarcoma of the extremities will undergo treatment of their primary tumor with either amputation or limb-sparing surgery and radiotherapy, and then be randomized to either observation or adjuvant treatment with doxorubicin and ifosfamide with mesna (with G-CSF) for five cycles beginning post-operatively.  Local recurrence, disease-free survival and overall survival will be evaluated in this randomized two-arm trial.</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/detailed_descr&gt;</div>
<div class="sdl1 sds">&lt;status_block&gt;</div>
<div class="sdl2 sds">&lt;status&gt;</div>
<div class="sdl3">  Completed</div>
<div class="sdl2 sdz">&lt;/status&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl3">  2000-04</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/status_block&gt;</div>
<div class="sdl1 sds">&lt;start_date&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl3">  1992-06</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/start_date&gt;</div>
<div class="sdl1 sds">&lt;end_date&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl3">  2001-03</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/end_date&gt;</div>
<div class="sdl1 sds">&lt;last_follow_up_date&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/last_follow_up_date&gt;</div>
<div class="sdl1 sds">&lt;last_data_entry_date&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/last_data_entry_date&gt;</div>
<div class="sdl1 sds">&lt;phase_block&gt;</div>
<div class="sdl2 sds">&lt;phase&gt;</div>
<div class="sdl3">  Phase 3</div>
<div class="sdl2 sdz">&lt;/phase&gt;</div>
<div class="sdl1 sdz">&lt;/phase_block&gt;</div>
<div class="sdl1 sds">&lt;study_type&gt;</div>
<div class="sdl2">  Interventional</div>
<div class="sdl1 sdz">&lt;/study_type&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Treatment</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Efficacy Study</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  Sarcoma</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;intervention&gt;</div>
<div class="sdl2 sds">&lt;intervent_type&gt;</div>
<div class="sdl3">  Drug</div>
<div class="sdl2 sdz">&lt;/intervent_type&gt;</div>
<div class="sdl2 sds">&lt;primary_name&gt;</div>
<div class="sdl3">  doxorubicin</div>
<div class="sdl2 sdz">&lt;/primary_name&gt;</div>
<div class="sdl1 sdz">&lt;/intervention&gt;</div>
<div class="sdl1 sds">&lt;intervention&gt;</div>
<div class="sdl2 sds">&lt;intervent_type&gt;</div>
<div class="sdl3">  Drug</div>
<div class="sdl2 sdz">&lt;/intervent_type&gt;</div>
<div class="sdl2 sds">&lt;primary_name&gt;</div>
<div class="sdl3">  ifosfamide</div>
<div class="sdl2 sdz">&lt;/primary_name&gt;</div>
<div class="sdl1 sdz">&lt;/intervention&gt;</div>
<div class="sdl1 sds">&lt;intervention&gt;</div>
<div class="sdl2 sds">&lt;intervent_type&gt;</div>
<div class="sdl3">  Drug</div>
<div class="sdl2 sdz">&lt;/intervent_type&gt;</div>
<div class="sdl2 sds">&lt;primary_name&gt;</div>
<div class="sdl3">  mesna</div>
<div class="sdl2 sdz">&lt;/primary_name&gt;</div>
<div class="sdl1 sdz">&lt;/intervention&gt;</div>
<div class="sdl1 sds">&lt;eligibility&gt;</div>
<div class="sdl2 sds">&lt;criteria&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  DISEASE CHARACTERISTICS:</div>
<div class="sdl4">  </div>
<div class="sdl4">  Histologically proven AR and ESFT which includes: Classical, atypical and extraosseous Ewing&amp;apos;s sarcoma, primitive peripheral neuroectodermal tumors, peripheral neuroepithelioma, primitive sarcoma of bone, and ectomesenchymoma.</div>
<div class="sdl4">  </div>
<div class="sdl4">  Confirmed presence of tumor-specific infusion protein by documented RT-PCR which corresponds to one of the tumor specific peptides available for vaccination.</div>
<div class="sdl4">  </div>
<div class="sdl4">  Measurable tumor.</div>
<div class="sdl4">  </div>
<div class="sdl4">  No prior or current CNS metastases.</div>
<div class="sdl4">  </div>
<div class="sdl4">  PRIOR/CONCURRENT THERAPY:</div>
<div class="sdl4">  </div>
<div class="sdl4">  Arm A patients:</div>
<div class="sdl4">  </div>
<div class="sdl4">  May be enrolled on the protocol for the first phase in the absence of RT PCR documentation of a tumor-specific fusion protein which corresponds to one of the tumor-specific peptides available for vaccination.  However, RT PCR documentation at the time of tumor recurrence must occur prior to administration of immunotherapy. At time of initial tumor diagnosis, prior to any cytoreductive therapy.</div>
<div class="sdl4">  </div>
<div class="sdl4">  Arm B patients:</div>
<div class="sdl4">  </div>
<div class="sdl4">  Tumor recurrence occurring during or after receiving at least first line cytoreductive therapy for ESFT and AR.  No more than two post-recurrence salvage regimens unless peripheral CD4+T  cell number is greater than 400 cells per millimeter cubed.</div>
<div class="sdl4">  </div>
<div class="sdl4">  At least 6 weeks since any treatments and recovered from all acute toxic effects from time in which immunotherapy will be started for this study.</div>
<div class="sdl4">  </div>
<div class="sdl4">  No concurrent estrogen therapy during immunotherapy section of study.</div>
<div class="sdl4">  </div>
<div class="sdl4">  PATIENT CHARACTERISTICS:</div>
<div class="sdl4">  </div>
<div class="sdl4">  Age:  2-25 (at time of initial diagnosis of alveolar rhabdomyosarcoma).</div>
<div class="sdl4">  </div>
<div class="sdl4">  Weight:  Greater than 15 kg (at time of apheresis).</div>
<div class="sdl4">  </div>
<div class="sdl4">  Performance status:  ECOG 0-2.</div>
<div class="sdl4">  </div>
<div class="sdl4">  Life expectancy:  At least 8 weeks.</div>
<div class="sdl4">  </div>
<div class="sdl4">  Hematopoietic:</div>
<div class="sdl4">  </div>
<div class="sdl4">  ANC greater than 100,000/mm3.</div>
<div class="sdl4">  </div>
<div class="sdl4">  Hemoglobin greater than 9.0 g/dL.</div>
<div class="sdl4">  </div>
<div class="sdl4">  Platelet count greater than 50,000/mm3.</div>
<div class="sdl4">  </div>
<div class="sdl4">  Hepatic:</div>
<div class="sdl4">  </div>
<div class="sdl4">  Bilirubin less than 2.0 mg/dL (unless related to involvement by tumor).</div>
<div class="sdl4">  </div>
<div class="sdl4">  Transaminases less than 3 times normal (unless related to involvement by tumor).</div>
<div class="sdl4">  </div>
<div class="sdl4">  Renal:</div>
<div class="sdl4">  </div>
<div class="sdl4">  Creatinine less than 1.5 mg/dL or creatinine clearance greater than 60 mL/min.</div>
<div class="sdl4">  </div>
<div class="sdl4">  Cardiovascular:</div>
<div class="sdl4">  </div>
<div class="sdl4">  No major disorder of cardiovascular system.</div>
<div class="sdl4">  </div>
<div class="sdl4">  Cardiac ejection fraction greater than 40%.</div>
<div class="sdl4">  </div>
<div class="sdl4">  Pulmonary:</div>
<div class="sdl4">  </div>
<div class="sdl4">  No major disorder of pulmonary system.</div>
<div class="sdl4">  </div>
<div class="sdl4">  Other:</div>
<div class="sdl4">  </div>
<div class="sdl4">  Not pregnant or nursing.</div>
<div class="sdl4">  </div>
<div class="sdl4">  HIV negative.</div>
<div class="sdl4">  </div>
<div class="sdl4">  Hepatitis B or C negative.</div>
<div class="sdl4">  </div>
<div class="sdl4">  No patients requiring daily oral corticosteroid therapy.</div>
<div class="sdl4">  </div>
<div class="sdl4">  If allergic to eggs, egg products, or thimerosal, or have a history of Guillain-Barre syndrome, ineligible to receive influenza vaccine.</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/criteria&gt;</div>
<div class="sdl2 sds">&lt;healthy_volunteers&gt;</div>
<div class="sdl3">  No</div>
<div class="sdl2 sdz">&lt;/healthy_volunteers&gt;</div>
<div class="sdl2 sds">&lt;patients&gt;</div>
<div class="sdl2 sdz">&lt;/patients&gt;</div>
<div class="sdl2 sds">&lt;expected_enrollment&gt;</div>
<div class="sdl3">  150</div>
<div class="sdl2 sdz">&lt;/expected_enrollment&gt;</div>
<div class="sdl2 sds">&lt;gender&gt;</div>
<div class="sdl3">  Both</div>
<div class="sdl2 sdz">&lt;/gender&gt;</div>
</div><div class="sdl2 sds">&lt;minimum_age&gt;</div>
</td>
</tr>
<tr class="sdiff-del" id="sdiff-chunk-m2"><td class="sdiff-h">2</td>
<td class="sdiff-a"><div class="sdl3">  N/A</div>
</td>
<td class="sdiff-b"><div class="sdl3"></div>
</td>
</tr>
<tr class="sdiff-unc" id="sdiff-chunk-m3"><td class="sdiff-h">3</td>
<td class="sdiff-a"><div class="sdl2 sdz">&lt;/minimum_age&gt;</div>
<div class="sdl2 sds">&lt;maximum_age&gt;</div>
</td>
<td class="sdiff-b"><div class="sdl2 sdz">&lt;/minimum_age&gt;</div>
<div class="sdl2 sds">&lt;maximum_age&gt;</div>
</td>
</tr>
<tr class="sdiff-del" id="sdiff-chunk-m4"><td class="sdiff-h">4</td>
<td class="sdiff-a"><div class="sdl3">  N/A</div>
</td>
<td class="sdiff-b"><div class="sdl3"></div>
</td>
</tr>
<tr class="sdiff-unc" id="sdiff-chunk-m5"><td class="sdiff-h">5</td>
<td class="sdiff-a"><img id="sdiff-collapse-m220A-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-m220&#39;)" style="display:none" /><img id="sdiff-collapse-m220A-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m220&#39;)" style="display:none" /><div class="sdl2 sdz">&lt;/maximum_age&gt;</div>
<div id="sdiff-collapse-m220A-cdiv" class="sdiff-collapsed" title="The middle 39 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m220&#39;)" style="display:none"></div><div id="sdiff-collapse-m220A-ediv" class="sdiff-expanded"><div class="sdl1 sdz">&lt;/eligibility&gt;</div>
<div class="sdl1 sds">&lt;background&gt;</div>
<div class="sdl2 sds">&lt;reference&gt;</div>
<div class="sdl3 sds">&lt;citation&gt;</div>
<div class="sdl4">  Lawrence W Jr, Donegan WL, Natarajan N, Mettlin C, Beart R, Winchester D.  Adult soft tissue sarcomas. A pattern of care survey of the American College of Surgeons. Ann Surg. 1987 Apr;205(4):349-59.</div>
<div class="sdl3 sdz">&lt;/citation&gt;</div>
<div class="sdl3 sds">&lt;medline_ui&gt;</div>
<div class="sdl4">  3566372</div>
<div class="sdl3 sdz">&lt;/medline_ui&gt;</div>
<div class="sdl2 sdz">&lt;/reference&gt;</div>
<div class="sdl2 sds">&lt;reference&gt;</div>
<div class="sdl3 sds">&lt;citation&gt;</div>
<div class="sdl4">  Alvegard TA, Sigurdsson H, Mouridsen H, Solheim O, Unsgaard B, Ringborg U, Dahl O, Nordentoft AM, Blomqvist C, Rydholm A, et al.  Adjuvant chemotherapy with doxorubicin in high-grade soft tissue sarcoma: a randomized trial of the Scandinavian Sarcoma Group. J Clin Oncol. 1989 Oct;7(10):1504-13.</div>
<div class="sdl3 sdz">&lt;/citation&gt;</div>
<div class="sdl3 sds">&lt;medline_ui&gt;</div>
<div class="sdl4">  2674336</div>
<div class="sdl3 sdz">&lt;/medline_ui&gt;</div>
<div class="sdl2 sdz">&lt;/reference&gt;</div>
<div class="sdl2 sds">&lt;reference&gt;</div>
<div class="sdl3 sds">&lt;citation&gt;</div>
<div class="sdl4">  Chang AE, Kinsella T, Glatstein E, Baker AR, Sindelar WF, Lotze MT, Danforth DN Jr, Sugarbaker PH, Lack EE, Steinberg SM, et al.  Adjuvant chemotherapy for patients with high-grade soft-tissue sarcomas of the extremity. J Clin Oncol. 1988 Sep;6(9):1491-500.</div>
<div class="sdl3 sdz">&lt;/citation&gt;</div>
<div class="sdl3 sds">&lt;medline_ui&gt;</div>
<div class="sdl4">  3047339</div>
<div class="sdl3 sdz">&lt;/medline_ui&gt;</div>
<div class="sdl2 sdz">&lt;/reference&gt;</div>
<div class="sdl1 sdz">&lt;/background&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  Adjuvant Chemotherapy</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  Ifosfamide</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  Randomized Study</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  Soft Tissue Sarcoma</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
</div><div class="sdl1 sds">&lt;initial_release_date&gt;</div>
</td>
<td class="sdiff-b"><img id="sdiff-collapse-m220B-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-m220&#39;)" style="display:none" /><img id="sdiff-collapse-m220B-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m220&#39;)" style="display:none" /><div class="sdl2 sdz">&lt;/maximum_age&gt;</div>
<div id="sdiff-collapse-m220B-cdiv" class="sdiff-collapsed" title="The middle 39 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m220&#39;)" style="display:none"></div><div id="sdiff-collapse-m220B-ediv" class="sdiff-expanded"><div class="sdl1 sdz">&lt;/eligibility&gt;</div>
<div class="sdl1 sds">&lt;background&gt;</div>
<div class="sdl2 sds">&lt;reference&gt;</div>
<div class="sdl3 sds">&lt;citation&gt;</div>
<div class="sdl4">  Lawrence W Jr, Donegan WL, Natarajan N, Mettlin C, Beart R, Winchester D.  Adult soft tissue sarcomas. A pattern of care survey of the American College of Surgeons. Ann Surg. 1987 Apr;205(4):349-59.</div>
<div class="sdl3 sdz">&lt;/citation&gt;</div>
<div class="sdl3 sds">&lt;medline_ui&gt;</div>
<div class="sdl4">  3566372</div>
<div class="sdl3 sdz">&lt;/medline_ui&gt;</div>
<div class="sdl2 sdz">&lt;/reference&gt;</div>
<div class="sdl2 sds">&lt;reference&gt;</div>
<div class="sdl3 sds">&lt;citation&gt;</div>
<div class="sdl4">  Alvegard TA, Sigurdsson H, Mouridsen H, Solheim O, Unsgaard B, Ringborg U, Dahl O, Nordentoft AM, Blomqvist C, Rydholm A, et al.  Adjuvant chemotherapy with doxorubicin in high-grade soft tissue sarcoma: a randomized trial of the Scandinavian Sarcoma Group. J Clin Oncol. 1989 Oct;7(10):1504-13.</div>
<div class="sdl3 sdz">&lt;/citation&gt;</div>
<div class="sdl3 sds">&lt;medline_ui&gt;</div>
<div class="sdl4">  2674336</div>
<div class="sdl3 sdz">&lt;/medline_ui&gt;</div>
<div class="sdl2 sdz">&lt;/reference&gt;</div>
<div class="sdl2 sds">&lt;reference&gt;</div>
<div class="sdl3 sds">&lt;citation&gt;</div>
<div class="sdl4">  Chang AE, Kinsella T, Glatstein E, Baker AR, Sindelar WF, Lotze MT, Danforth DN Jr, Sugarbaker PH, Lack EE, Steinberg SM, et al.  Adjuvant chemotherapy for patients with high-grade soft-tissue sarcomas of the extremity. J Clin Oncol. 1988 Sep;6(9):1491-500.</div>
<div class="sdl3 sdz">&lt;/citation&gt;</div>
<div class="sdl3 sds">&lt;medline_ui&gt;</div>
<div class="sdl4">  3047339</div>
<div class="sdl3 sdz">&lt;/medline_ui&gt;</div>
<div class="sdl2 sdz">&lt;/reference&gt;</div>
<div class="sdl1 sdz">&lt;/background&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  Adjuvant Chemotherapy</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  Ifosfamide</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  Randomized Study</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  Soft Tissue Sarcoma</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
</div><div class="sdl1 sds">&lt;initial_release_date&gt;</div>
</td>
</tr>
<tr class="sdiff-chg" id="sdiff-chunk-m6"><td class="sdiff-h">6</td>
<td class="sdiff-a"><div class="sdl2"><span class="sdwc">2006-07-14</span> </div>
</td>
<td class="sdiff-b"><div class="sdl2"><span class="sdwc">1999-11-03</span> </div>
</td>
</tr>
<tr class="sdiff-unc" id="sdiff-chunk-m7"><td class="sdiff-h">7</td>
<td class="sdiff-a"><img id="sdiff-collapse-m262A-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-m262&#39;)" style="display:none" /><img id="sdiff-collapse-m262A-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m262&#39;)" style="display:none" /><div class="sdl1 sdz">&lt;/initial_release_date&gt;</div>
<div id="sdiff-collapse-m262A-cdiv" class="sdiff-collapsed" title="The middle 3 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m262&#39;)" style="display:none"></div><div id="sdiff-collapse-m262A-ediv" class="sdiff-expanded"><div class="sdl1 sds">&lt;last_release_date&gt;</div>
<div class="sdl2">  2006-07-14</div>
<div class="sdl1 sdz">&lt;/last_release_date&gt;</div>
</div><div class="sdl0 sdz">&lt;/clinical_study&gt;</div>
</td>
<td class="sdiff-b"><img id="sdiff-collapse-m262B-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-m262&#39;)" style="display:none" /><img id="sdiff-collapse-m262B-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m262&#39;)" style="display:none" /><div class="sdl1 sdz">&lt;/initial_release_date&gt;</div>
<div id="sdiff-collapse-m262B-cdiv" class="sdiff-collapsed" title="The middle 3 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m262&#39;)" style="display:none"></div><div id="sdiff-collapse-m262B-ediv" class="sdiff-expanded"><div class="sdl1 sds">&lt;last_release_date&gt;</div>
<div class="sdl2">  2006-07-14</div>
<div class="sdl1 sdz">&lt;/last_release_date&gt;</div>
</div><div class="sdl0 sdz">&lt;/clinical_study&gt;</div>
</td>
</tr>

</table></div></form><div class="navBottom"><div class="navBottomLine" style="background-image: url(/archive/ctgov_logo_ttm.gif)">&#160;</div><div class="navBottomLinks">&#160;</div></div><script>
SDiffDeclareUnchCRID('sdiff-collapse-f0');
SDiffDeclareUnchCRID('sdiff-collapse-f220');
SDiffDeclareUnchCRID('sdiff-collapse-f285');
SDiffDeclareUnchCRID('sdiff-collapse-m0');
SDiffDeclareUnchCRID('sdiff-collapse-m220');
SDiffDeclareUnchCRID('sdiff-collapse-m262');
SDiffInit();
</script></body></html>